LAVA Therapeutics (LVTX) News Today $2.07 -0.04 (-1.90%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 21, 2024 | americanbankingnews.comLAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% June 20, 2024 | globenewswire.comLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 10, 2024 | globenewswire.comLAVA Announces Annual Meeting of ShareholdersMay 30, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 21, 2024 | seekingalpha.comLAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20, revenue of $6.99M beats by $3.49MMay 21, 2024 | globenewswire.comLAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 6, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | msn.comLava gets $7M from Pfizer as trial for cancer drug advancesMarch 5, 2024 | globenewswire.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | marketbeat.comLAVA Therapeutics (NASDAQ:LVTX) Trading Up 37.7%LAVA Therapeutics (NASDAQ:LVTX) Trading 37.7% HigherMarch 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)February 21, 2024 | benzinga.comLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest ReportFebruary 14, 2024 | investing.comLAVA Therapeutics NV (LVTX)January 25, 2024 | msn.comLava signs collaboration agreement with MSD for prostate cancer therapyJanuary 25, 2024 | seekingalpha.comPCSA, ONCO and KAVL among mid-day moversJanuary 25, 2024 | finance.yahoo.comLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®December 13, 2023 | ca.finance.yahoo.comLAVA Therapeutics N.V. (LVTX)November 11, 2023 | morningstar.comLAVA Therapeutics NV LVTXAugust 25, 2023 | bizjournals.comLava Therapeutics is latest life sciences company to trim its workforceAugust 22, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finance.yahoo.comLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsJuly 6, 2023 | msn.comLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34June 14, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayJune 14, 2023 | msn.comLava Therapeutics shelves hematology drug over competitive concernsJune 12, 2023 | msn.comHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy RecommendationJune 9, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)June 1, 2023 | finance.yahoo.comLAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 30, 2023 | finance.yahoo.comLAVA Announces Annual Meeting of ShareholdersMay 30, 2023 | uk.finance.yahoo.comIs a Beat Likely for Cooper Companies (COO) in Q2 Earnings?April 17, 2023 | benzinga.comLAVA Therapeutics Stock (NASDAQ:LVTX), DividendsApril 12, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for LAVA Therapeutics (LVTX)April 11, 2023 | finance.yahoo.comLAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comLAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsFebruary 16, 2023 | finance.yahoo.comLAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumFebruary 9, 2023 | finance.yahoo.comLAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceFebruary 6, 2023 | markets.businessinsider.comLAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical OfficerJanuary 27, 2023 | marketbeat.comLAVA Therapeutics (NASDAQ:LVTX) Sees Significant Drop in Short InterestLAVA Therapeutics (NASDAQ:LVTX - Get Rating) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 3,900 shares, a decrease of 38.1% from the December 31st total of 6,300 shares. Based on an average daily volume of 38,500 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short.January 26, 2023 | seekingalpha.comLVTX LAVA Therapeutics N.V.January 23, 2023 | finance.yahoo.comLAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumJanuary 6, 2023 | finance.yahoo.comLAVA Therapeutics Announces Appointment of New Directors to the BoardJanuary 3, 2023 | finance.yahoo.comLAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 10, 2022 | finance.yahoo.comLAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 14, 2022 | finance.yahoo.comWill LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should KnowNovember 4, 2022 | finance.yahoo.comLAVA Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comLAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 1, 2022 | finance.yahoo.comLAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. LVTX Media Mentions By Week LVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LVTX News Sentiment▼1.140.62▲Average Medical News Sentiment LVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LVTX Articles This Week▼30▲LVTX Articles Average Week Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evelo Biosciences News Grifols News Mainz Biomed News NLS Pharmaceutics News Pharvaris News Procaps Group News Qilian International Holding Group News Adicet Bio News Shattuck Labs News Editas Medicine News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LVTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
